Assessing Gene Therapy to Upregulate Three Longevity-Associated Genes in Mice
In this study, we developed gene therapies based on 3 longevity associated genes: fibroblast growth factor 21 (FGF21), αKlotho, soluble form of mouse transforming growth factor-β receptor 2 (sTGFβR2). The gene therapies were delivered using adeno-associated viruses, and we explored their ability to mitigate 4 age-related diseases: obesity, type II diabetes, heart failure, and renal failure. Individually and combinatorially, we applied these therapies to disease-specific mouse models and found that this set of diverse pathologies could be effectively treated and in some cases, even reversed with a single dose. We observed a 58% increase in heart function in ascending aortic constriction ensuing heart failure, a 38% reduction in α-smooth muscle actin (αSMA) expression, and a 75% reduction in renal medullary atrophy in mice subjected to unilateral ureteral obstruction and a complete reversal of obesity and diabetes phenotypes in mice fed a constant high-fat diet. Crucially, we discovered that a single formulation combining 2 separate therapies into 1 was able to treat all 4 diseases. These results emphasize the promise of gene therapy for treating diverse age-related ailments and demonstrate the potential of combination gene therapy that may improve health span and longevity by addressing multiple diseases at once.
HOW TO get rid of visceral fat: Visceral fat ’s positioning in the body means carrying an excess amount of it could have potentially deadly consequences. Diet can drastically reduce or increase the build-up of visceral fat and evidence makes a strong case for cutting down on a certain culprit.
Is the seated saline infusion test an accurate means of determining primary aldosteronism subtypes? How does it compare with other tests?Clinical Endocrinology
TYPE 2 diabetes is a chronic condition that requires a person to overhaul aspects of their lifestyle to keep rising blood sugar levels in check. Diet plays a decisive role in regulating blood sugar and warding off the threat of developing serious conditions and evidence is increasingly singling out certain items for their blood sugar-lowering benefits, including a certain fruit.
Background Diabetes mellitus predicts poorer outcomes in patients with acute coronary syndrome (ACS), but the magnitude of this association in patients at older ages remains controversial. Methods Data were extracted from the Codi Infart database. All consecutive patients with diagnosis of ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) between 2010 and 2015 were included. We assessed the impact of diabetes mellitus on 30-day and one-year mortality in patients aged less than and at least 75 years. Results A total of 12 792 cases were registered, of whom...
Conclusion: Sirolimus-eluting Stentys stent may represent a potential solution for specific coronary anatomies such as bifurcation, ectasic, or tapered vessels. Risk of stent thrombosis appears related to clinical presentation with STEMI and to anatomic features, stressing the importance of the use of intracoronary imaging for self-expandable stents implantation.
Background We hypothesized that the transition from bare-metal stents (BMS) to newer generation drug-eluting stents (n-DES) in clinical practice may have reduced the risk also in patients with kidney dysfunction. Methods: Observational study in the national SWEDEHEART registry, that compared the 1-year risk of in-stent restenosis (RS) and stent thrombosis (ST) in all percutaneous coronary intervention treated patients(n = 92 994) during 2007–2013. Results: N-DES patients were younger than BMS, but had more often diabetes, previous myocardial infarction, previous revascularization and were more often treated w...
No abstract available
Date: Friday, 12 13, 2019; Speaker: Jonathan Epstein, M.D., William Wikoff Smith Professor/Exec. Vice Dean, University of Pennsylvania; Building: Building 6B; 4B429 4th floor library
A subanalysis of CREDENCE suggests that SGLT2 inhibitor use should be based on clinical benefit, not solely glycemic control, say researchers. Another study hints that these drugs up EPO levels.Medscape Medical News
This review examined the impact of weight loss on pre-existing psoriasis or psoriatic arthritis. Might losing weight prevent the onset of psoriasis in obese individuals?The British Journal of Dermatology
More News: Adenoviruses | Biochemistry | Biotechnology | Cardiology | Cardiovascular | Children | Diabetes | Diets | Eating Disorders & Weight Management | Endocrinology | Gastroschisis Repair | Gene Therapy | Genetics | Heart | Heart Failure | High Fat | Nutrition | Obesity | Renal Failure | Research | Study | Ureter and Renal Pelvis Cancer | Urology & Nephrology